MONSEY, N.Y., June 28, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether Elanco Animal Health Incorporated (NYSE:ELAN) (“Elanco”) has violated federal securities laws after the company announced that the U.S. label for its new eczema treatment for dogs, Zenrelia, will include an unexpected boxed warning on safety. Elanco also announced a delay in the launch of Zenrelia to the fourth quarter. Upon this news, Elanco shares fell over 20% in trading on June 27, 2024.
If you are an Elanco shareholder and have suffered losses, you may contact us at the following link to discuss your legal rights and options at no charge:
https://wohlfruchter.com/cases/elanco-animal-health/
Alternatively, you may contact us by phone at 866-833-6245, or via email at alerts@wohlfruchter.com.
Why is there an investigation?
On June 27, 2024, Elanco announced that the U.S. label for Zenrelia will carry a boxed warning to highlight safety concerns. Elanco further advised that it expected this warning to slow adoption of Zenrelia in the U.S. and initially limit the number of expected treatment days by approximately 25%. Elanco indicated that it plans to conduct additional research to resolve the issue.
Elanco also announced a delay in the launch of Zenrelia to the fourth quarter.
Upon this news, Elanco shares fell over 20% in trading on June 27, 2024.
About Wohl & Fruchter
Wohl & Fruchter LLP, with offices in New York City and Monsey, has for over a decade been representing investors in litigation arising from fraud and other corporate misconduct, and recovered hundreds of millions of dollars in damages for investors. Please visit our website, www.wohlfruchter.com, to learn more about our Firm, or contact one of our partners.
Contact:
Wohl & Fruchter LLP
Joshua E. Fruchter
Toll Free 866.833.6245
alerts@wohlfruchter.com
www.wohlfruchter.com
Source:
Wohl & Fruchter LLP2024 GlobeNewswire, Inc., source Press Releases
ELANCO ANIMAL HEALTH INCORPORATED 
